We're giving boosters of a vaccine developed against the Beta variant. That's better than nothing. But it's inefficient against Delta.
Pfizer/BioNTech are working on a Delta-specific booster [1]. If we can get approvals rolling faster without compromising safety, it might mean being able to release variant-specific boosters earlier in their transmission cycle.
[1] https://investors.biontech.de/news-releases/news-release-det...